WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 13, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
completed its previously announced acquisition of nContact, Inc., a
privately held developer of innovative cardiac ablation solutions.
About AtriCure
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. Afib affects more than 33 million people worldwide. For
more information visit AtriCure.com
or follow us on Twitter @AtriCure.
About nContact
nContact’s mission is to transform the underserved arrhythmia market
through the advancement of less invasive ablation alternatives for
cardiac arrhythmias. The Company is conducting the CONVERGE IDE Clinical
Trial, the first head-to-head study to evaluate the Convergent Procedure
to catheter ablation in persistent atrial fibrillation patients. The
Company’s lead technology, Epi-Sense® Coagulation System with VisiTrax®,
has CE Mark approval in Europe for the coagulation of cardiac tissue in
the treatment of atrial fibrillation and atrial flutter. The Epi-Sense
Coagulation System with VisiTrax is indicated for endoscopic coagulation
of cardiac tissue in the U.S. nContact was founded in 2005 and is
headquartered in Morrisville, North Carolina, USA. For more information,
visit www.ncontactinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151013006892/en/
Source: AtriCure, Inc.
AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice
President and Chief Financial Officer
awade@AtriCure.com
or
Investor
Relations Contact
Westwicke Partners
Lynn Pieper,
415-202-5678
lynn.pieper@westwicke.com
